TFF Pharmaceuticals announced that the Company will present data from the Phase 2 trial of Voriconazole Inhalation Powder, TFF VORI, for the treatment of invasive pulmonary aspergillosis at the upcoming Advances Against Aspergillosis & Mucormycosis, AAAM, Conference, which will be held from January 25-27, 2024, in Milan, Italy. Data being presented at the AAAM Conference were first disclosed by the Company in December 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TFFP:
- TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference
- Biotech Alert: Searches spiking for these stocks today
- TFF Pharmaceuticals reports positive initial data from Phase 2 trials of TFF
- TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC
- TFF Pharmaceuticals trading halted, news pending